Clinical trial data of imetelstat in individuals with breast cancer presented at ASCO annual meeting Geron Corporation today announced the presentation of data from the clinical trial of imetelstat , the company’s telomerase inhibitor drug, in conjunction with paclitaxel and bevacizumab in sufferers with breast cancer in the 2010 American Society of Clinical Oncology annual conference in Chicago. The trial may also explore predictive biomarkers to preferentially select breast malignancy patients who may benefit from telomerase inhibition before sexual stimulation .
The cumulative success rates for biologic and small-molecule drugs for advanced NSCLC were less than industry aggregate rates; the price for small-molecule drugs was 17 percent and the price for biologic medicines was 10 percent . When the influence of the mechanism of action was analyzed, the cumulative success rate was 31 percent for receptor targeted therapies, such as for example bevacizumab, crizotinib, erlotinib, and gefitinib, which was nearly threefold better than nontargeted treatments . The rate was lowest for immunotherapy. Our analysis suggests that biomarker targeted treatment indications and substances that have a receptor targeted system of action provide best chance of clinical success in this indication and should be the focus of future medical trial development, says initial writer Adam Falconi, BSc, Pharm, of the Department of Pharmacy, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.